Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price reached a new 52-week high on Friday . The stock traded as high as $260.98 and last traded at $256.35, with a volume of 102450 shares trading hands. The stock had previously closed at $244.20.
Beigene Stock Up 4.6 %
The company has a market cap of $24.99 billion, a PE ratio of -30.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.
Insiders Place Their Bets
In other Beigene news, COO Xiaobin Wu sold 21,267 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 7.43% of the company’s stock.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Featured Stories
- Five stocks we like better than Beigene
- How to Plot Fibonacci Price Inflection Levels
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Comparing and Trading High PE Ratio Stocks
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Calculate Retirement Income: MarketBeat’s Calculator
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
